Abbreviations & Acronyms a1-blocker = a1-adrenergic receptor blocker 5ARI = 5-alpha-reductase inhibitor BII = benign prostatic hyperplasia impact index BOO = bladder outlet obstruction BOOI = bladder outlet obstruction index BPH = benign prostatic hyperplasia DO = detrusor overactivity FDV = first desire to void IPSS = International Prostate Symptom Score IQR = interquartile range LUTD = lower urinary tract dysfunctions LUTS/BPH = lower urinary tract symptoms suggestive of benign prostatic hyperplasia LUTS = lower urinary tract symptoms MCC = maximum cystometric capacity OABSS = overactive bladder symptom score PDE5 = phosphodiesterase 5 PdetQ max = detrusor pressure at maximum flow rate PFS = pressure flow study PVR = post-void residual urine volume Q max = maximum urinary flow rate QOL = quality of life UDS = urodynamic study Objective: To investigate the effects of tadalafil on storage and voiding function in treatment-na€ ıve patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, based on a urodynamic study.
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Introduction
Current guidelines for the treatment of BPH in several countries recommend the use of a1-blockers or 5ARIs, or PDE5 inhibitors for patients with LUTS/BPH. [1] [2] [3] [4] a1-Blockers, such as tamsulosin and silodosin, which are popular and frequently prescribed a1-blockers, improve LUTS/BPH by relaxing the smooth muscle tone of the prostate and bladder neck.
5 5ARIs, such as dutasteride and finasteride, were reported to improve LUTS by decreasing prostate size through inhibition of 5AR. 6 These medical agents were reported to improve not only subjective symptoms, but also lower urinary tract functions, such as storage function and BOO. [7] [8] [9] Meanwhile, tadalafil is the only PDE5 inhibitor approved for patients with LUTS/BPH. Smooth muscle relaxation in the bladder, urethra and prostate as a result of increased nitric oxide/cyclic guanosine monophosphate pathway activity through inhibition of PDE5 isoenzymes was reported to be the mechanism of LUTS improvement with tadalafil. 10 Additionally, some papers reported that not only a1-blockers, but also PDE5 inhibitors increase blood perfusion to the pelvic area, and this contributes to the improvement of LUTS and LUTD. 11, 12 In fact, tadalafil was reported in many studies to significantly improve LUTS; [13] [14] [15] in our clinical experience, tadalafil has a beneficial effect on the improvement of subjective symptoms.
However, some papers reported that tadalafil did not show a significant improvement in urinary flow rate as compared with a placebo. 16, 17 In particular, Dmochowski et al. reported that tadalafil treatment for LUTS/BPH showed no beneficial impact on BOO. 18 To the best of our knowledge, few studies have focused on the objective effects of this drug on both storage and voiding functions based on a urodynamic study. As just described, although tadalafil has been shown to improve LUTS significantly, little is known about its effect on LUTD. Some issues remain to be investigated, including the discrepancy between the improvement in subjective symptoms and objective findings with tadalafil. The principal aim of the present study was to determine whether tadalafil has an objective effect on storage function and BOO in patients with LUTS/BPH, based on UDS.
Methods
This was a single-center, open-label, prospective study, which was carried out in accordance with the ethical principles of the Declaration of Helsinki. The protocol was approved by the ethics committee of the Nagoya University Graduate School of Medicine (IRB approval number: 2015-0106). All participants provided written informed consent before enrollment. This study was registered at https://center.umin.ac.jp as UMIN000017925.
The study included treatment-na€ ıve men who visited Nagoya University Hospital, Nagoya, Japan, with a chief complaint of both storage and voiding LUTS between June 2015 and March 2016. The inclusion criteria were as follows: total IPSS ≥8; IPSS-QOL score ≥3; prostate volume ≥25 mL as determined by transabdominal ultrasonography; Q max <15 mL/s at voided volume of ≥100 mL; residual urine <150 mL; and age ≥50 years. Patients were excluded if they had received oral treatment with a1-blockers, anticholinergic agents, 5ARI, antidepressants, anti-anxiety agents, sex hormone agents, nitroglycerin, amyl nitrite or isosorbide dinitrate; had neurogenic bladder dysfunction, bladder calculi or active urinary tract infections; or had severe cardiac disease, renal dysfunction (serum creatinine level ≥2 mg/dL) and/or hepatic dysfunction (aspartate and alanine aminotransferase concentrations more than twice the normal values). Prostate biopsy was carried out in all patients who had prostate-specific antigen levels >4 ng/mL, and only cancer-free patients were included in the study.
Patients who satisfied all the inclusion and exclusion criteria received tadalafil (5 mg/day) for 12 weeks. The IPSS, IPSS-QOL, OABSS and BII were measured before and after drug administration to evaluate subjective symptom severity and QOL. Patients also underwent UDS, including uroflowmetry, cystometrogram and PFS, to evaluate their lower urinary tract function before and 12 weeks after administration. FDV, MCC and DO were assessed as parameters of storage function. Q max , PVR, PdetQ max and BOOI were evaluated as parameters of voiding function. BOOI was calculated according to the following formula: PdetQ max À 2Q max . Patients were diagnosed with obstruction if BOOI was >40, equivocal if BOOI was 20-40 and unobstructed if BOOI was <20, according to the International Continence Society nomogram. 19, 20 An apparent improvement in DO was defined as its disappearance. A cystometrogram and PFS were carried out by one author (YM) according to standard methods defined by the International Continence Society. 20 ,21 UDS data were de-identified and analyzed independently by two of our research group members (YF and MK) who were not involved in carrying out UDS.
We calculated the target enrollment number based on previous studies, and a clinically relevant change in PdetQ max of 15 cmH 2 O was used. 18, 22 The expected mean change (standard deviation) for the change of PdetQ max from baseline was assumed to be 10 cmH 2 O (12.5 cmH 2 O). The sample size required to determine this change was 68 when the two-sided alpha level and power were assumed to be 5% and 90%, respectively. Finally, a total of 80 cases were calculated as the required number of cases, considering a dropout rate of 15%. Patients were excluded from the analysis if they discontinued treatment because of adverse reactions, or if urodynamic assessment data were not collected until 12 weeks of treatment.
All statistical values are represented as mean AE standard deviation and median (interquartile range). The Wilcoxon signed-rank test and McMemar test were carried out to evaluate changes in subjective symptoms, including IPSS, OABSS, and objective findings obtained by cystometrogram and PFS. All tests were two-sided, and a P-value <0.05 was considered statistically significant. All statistical analyses were carried out using SPSS software (IBM, Armonk, NY, USA).
Results
Of 80 patients who met the entry criteria, four (5.0%) discontinued treatment owing to adverse reactions, including headache (n = 2), problem on erection (n = 1) and dizziness (n = 1). One patient developed urinary retention during the study period. UDS was not carried out after treatment in four patients. As a result, the analysis included 71 patients with a mean age of 70.2 years (range 51-85 years) and a mean prostate volume of 45.6 mL (range 25.2-87.1 mL). All patients were Japanese. Patient characteristics at baseline are shown in Table 1 . A total of 30 (42.3%) patients had an IPSS ≥20 (severe subjective symptoms), 58 (81.7%) patients had BOO based on PFS (BOOI >40), and 39 (54.9%) and 26 (36.7%) patients received pharmacotherapy for hypertension and hyperlipidemia, respectively. A total of 12 patients (16.9%) had diabetes. Table 2 summarizes changes in subjective symptoms and objective findings. A significant decrease in IPSS was observed. After 12 weeks, the mean reduction in score was 4.8 points (26.3%). Significant decreases were also observed in IPSS subscores for voiding and storage, IPSS-QOL, OABSS, and BII. Although 48 patients (67.6%) fulfilled the criteria of OAB (total OABSS ≥3 and urinary urgency ≥1 per week) at baseline, the number of patients diagnosed as having OAB according to the diagnostic criteria of OABSS decreased to 27 (38.0%) 12 weeks after administration.
Regarding voiding function, Q max increased, with a significant improvement after 12 weeks. An increase of 2.0 mL/s (28.2%) was observed. Mean PdetQ max changed from 75.5 to 65.2 cmH 2 O, and decreased by 10.3 cmH 2 O after 12 weeks. Mean BOOI changed significantly from 61.3 to 47.1 (P < 0.001; Fig. 1a ). At baseline, 58 patients (81.7%) had BOO (BOOI >40), whereas the number of patients with BOO declined to 40 patients (56.3%) after 12 weeks, representing a substantial improvement. Regarding storage function, based on the UDS results, we observed a statistically significant improvement in FDV and MCC. Additionally, although DO was present in 38 patients (53.5%) before treatment, it disappeared in 15 of 38 patients (39.5%) after tadalafil administration (P < 0.001; Fig. 1b) .
Discussion
The primary end-point of the present study was to evaluate the effect of tadalafil at a 5-mg daily dose, given in clinical practice, on storage and voiding functions in patients with LUTS/BPH, using sophisticated urodynamic examinations. Up to now, a number of studies have reported that tadalafil provides statistically and clinically meaningful improvement in subjective symptoms of the lower urinary tract; [13] [14] [15] however, little has been reported on the objective effects of tadalafil.
Despite substantial evidence suggesting the efficacy of tadalafil to improve LUTD being clarified in basic research studies -tadalafil induces smooth muscle relaxation in the prostate and bladder, 23 negatively regulates proliferation and transdifferentiation of the lower urinary tract, 23 ,24 decreases afferent nerve activity, 23, 25 improves LUTS-related inflammation, 23, 26 and increases blood flow of the lower urinary tract 23, 27 -some studies reported that tadalafil did not improve Q max significantly in clinical studies. 16, 17 Recently, Roehrborn et al. reported small, but statistically significant, changes in median Q max with tadalafil versus placebo on post-hoc integrated analysis of data from four international pivotal studies. 28 However, few studies have focused on the effects of tadalafil on both storage functions and BOO, and the present study was prospectively carried out to provide new evidence regarding the storage and voiding function effects of tadalafil.
Dmochowski et al. reported no significant difference between tadalafil and placebo treatment in terms of mean change in any urodynamic parameter, such as PdetQ max . 18 They reported that a change of PdetQ max from baseline to end-point was -2.1 cmH 2 O in patients treated with tadalafil. In contrast, in the present study, the mean PdetQ max significantly improved from 75.5 to 65.2 cmH 2 O, a change of 10.3 cmH 2 O. BOOI also improved by 23.2% (from 61.3 to 47.1) after 12 weeks' administration of tadalafil. We were unable to identify a precise explanation for the different effects detected in terms of the effect of tadalafil on BOO between Regarding storage function, MCC increased significantly from baseline, by approximately 35 mL, and DO was eliminated in approximately 40% of patients 12 weeks after tadalafil administration. Although the detailed mechanism by which tadalafil significantly improves storage function in clinical practice is incompletely understood, the actions of tadalafil, such as decreased afferent nerve activity 23, 25 and increased blood flow to the bladder, 12, 23, 27 is thought to be related to the clinical effect. This finding is thought to be important when selecting a therapeutic strategy for LUTS/BPH.
Meanwhile, although available a1-blockers, currently used as the first choice for patients with LUTS/BPH, have different profiles of receptor selectivity, each a1-blocker has been reported to improve not only subjective symptoms, but also BOO. Fusco et al. reviewed the urodynamic efficacy of a1-blockers. 7 They reported that the overall pooled data on the improvement of a1-blockers showed a mean BOOI change of À14.19 (P < 0.001), a mean PdetQ max change of À11.39 cmH 2 O (P < 0.001) and a mean Q max improvement of 2.27 mL/s (P < 0.001). Additionally, subgroup analysis showed a mean BOOI change of À14.88 (P = 0.01) with alfuzosin, À19.41 (P = 0.01) with doxazosin, À16.47 (P < 0.001) with naftopidil, À30.45 (P < 0.001) with silodosin, À14.27 (P = 0.002) with tamsulosin and À6.69 (P = 0.005) with terazosin. When comparing these results with the present findings on the urodynamic efficacy of tadalafil, which showed a mean BOOI change of À14.2, a mean PdetQ max change of À10.3 cmH 2 O and a mean Q max improvement of 2.0 mL/s, the ameliorating effect is almost equal, and tadalafil is thus thought to have equivalent efficacy, compared with a1-blockers, in terms of improvement in not only subjective symptoms, but also BOO. Furthermore, tadalafil might have an additional benefit in terms of relieving OAB symptoms in LUTS/BPH patients.
The present study had some limitations. First, this was an open-label and not a placebo-controlled study. Therefore, placebo effects cannot be completely excluded in terms of subjective symptom changes as well as UDS outcomes. However, these effects were minimal, and were not likely to have affected the objectivity of the present study in a major manner. Furthermore, observer bias when analyzing UDS cannot be ruled out, but we believe that this did not seriously affect our study outcomes, as the UDS data were anonymized and analyzed independently by two of our research group members who were not involved in UDS data acquisition. Another limitation was that the follow-up period of the present study was just 12 weeks. As pharmacotherapy for LUTS should generally be continued for a much longer period, the long-term efficacy and safety of tadalafil therapy for patients with LUTS/BPH need to be further clarified in future studies.
In conclusion, 12 weeks' treatment with tadalafil significantly improved lower urinary tract functions, in terms of bladder capacity, DO, Q max and BOOI. Tadalafil effectively relieved LUTS by improving storage and voiding function, as well as subjective symptoms in patients with LUTS/BPH.
